TB-500 (Thymosin Beta-4) Research Peptide (RUO)

What is TB-500 (Thymosin Beta-4)?

TB-500 is a synthetic analogue of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in nearly all mammalian cells. The molecule (CAS 77591-33-4, molecular formula C212H350N56O78S, ~4963.44 g/mol) is N-terminally acetylated and is the principal G-actin-sequestering peptide in many cell types, binding monomeric (globular) actin in a 1:1 complex and thereby modulating the pool of actin available for polymerisation into filaments. Through this actin-regulating activity and interactions with additional molecular partners, it has been studied in research models of cell migration, angiogenesis and tissue repair.

It is important to state the regulatory position clearly: TB-500 / thymosin beta-4 is not approved by the FDA, EMA or other major regulators for any therapeutic indication, and it is prohibited in sport under the WADA Prohibited List. No efficacy or therapeutic-benefit claims are made for this molecule.

How TB-500 Is Produced & Characterised

At 43 residues with an acetylated N-terminus and a high content of glutamate and lysine, TB-500 is a synthetically demanding peptide in which deletion sequences, incomplete acetylation and closely related variants must be tightly controlled. In an industry setting this peptide class is typically produced by optimised Fmoc solid-phase peptide synthesis (SPPS), followed by preparative dynamic axial compression (DAC) HPLC purification to resolve the target sequence sharply from related impurities, and then lyophilisation to a stable, uniform powder.

Characterisation generally relies on UPLC/HPLC for purity determination and LC-MS for confirming the sequence and profiling minor structural variants. Controlled N-terminal acetylation and tight control of deletion sequences and related variants are central to producing a well-defined material with repeatable batch-to-batch consistency, from gram-scale research lots through to larger reference-standard campaigns.

Regulatory Status & Handling

TB-500 / thymosin beta-4 is not an approved drug substance and is not approved by the FDA, EMA or other major regulators for any therapeutic indication. It is handled strictly for research and reference-standard purposes and is not represented as suitable for finished human pharmaceutical products. It is also prohibited at all times in sport under the WADA Prohibited List (class S2).

As a peptide, TB-500 is typically presented as a lyophilised powder and stored at -20°C, protected from light and moisture. Nothing on this page is medical or patient advice.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade TB-500 to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to TB-500 in their country.